

FDA Reform, Clinical Trial Design Changes Urged

BY MARY ELLEN SCHNEIDER
New York Bureau

BOSTON — Any proposals to reform the Food and Drug Administration should meet the test that the changes would have prevented the arthritis drug Vioxx from getting to the market, Dr. David J. Graham said at the annual meeting of the American Public Health Association.

Dr. Graham, an FDA scientist who testified before Congress in 2004 about the unwillingness of FDA officials to recognize safety problems with Vioxx (rofecoxib), was among a panel of experts who called for changes at the FDA and reforms in the way that pharmaceutical companies design clinical trials.

The criticism comes on the heels of a report from the Institute of Medicine that recommends significant reforms at the FDA, including the establishment of performance goals for safety.

The FDA has been "captured" by the industry and has taken on the value system of the pharmaceutical companies, said Dr. Graham, of the FDA Office of Surveillance and Epidemiology, who was speaking as an individual and not on behalf of the agency.

FDA officials now see their jobs as getting drugs on the market as fast as possible, Dr. Graham said. "We have at FDA a lack of checks and balances."

FDA leadership was quick to rebut those charges. The vast majority of physicians, scientists, and staff members at the FDA reject the concept that the agency is beholden to the drug industry, Dr. Steven Galson, director of the Center for Drug Evaluation and Research (CDER), said.

In light of calls for reform, FDA officials have already taken a series of steps over the last 2 years to try to improve the processes within the agency, Dr. Galson said. For example, the agency has created a new drug safety oversight board that includes individuals from the FDA and other government agencies to provide advice on drug safety issues, and it has increased the number of staff working in the postmarketing safety area. FDA officials have also redesigned the drug label so that physicians can quickly see the key information they need to make prescribing decisions.

But the biggest advances in drug safety are more likely to come from basic science advances, he said. These advances, which the FDA is trying to foster through its Crit-

ical Path Initiative, will help scientists better predict which drugs in development will run into safety problems later.

But the FDA also should improve its post-marketing surveillance, said panelist Dr. John D. Abramson, a clinical instructor in the department of ambulatory care and prevention at Harvard Medical School, Boston. The current system—in which physicians voluntarily report drug-related adverse events—does not work, because it's passive, he said. The FDA could instead be doing epidemiologic studies to monitor side effects in the entire population taking a drug.

Panelists also took aim at how the pharmaceutical industry designs clinical trials. Drug trials are conducted primarily to maximize return on investment to shareholders by emphasizing benefits of the drug and minimizing risks, Dr. Abramson said.

Drug companies used to simply provide financial support for studies, but they now also design the study and keep the research, said panelist Dr. Marcia Angell, former editor-in-chief of the New England Journal of Medicine and a senior lecturer on social medicine at Harvard.

One possible way to limit the influence of pharmaceutical companies in study de-

sign would be to create an arm of the National Institutes of Health that would oversee the design of trials, Dr. Angell said, adding that such a body could be wholly or partially funded by industry. Registration of clinical trials at their inception should be a requirement to enroll human subjects, she said.


The panel also criticized the FDA statute that requires new drugs to show effectiveness compared with placebo, but does not require a new drug to be better than existing medications on the market. This leads to approval of drugs with limited benefits and unknown risks, Dr. Angell said.

She cited Vioxx as an example of a drug that should never have been approved because it had only marginal benefits over existing drugs to treat the same condition. In Dr. Angell's opinion, any FDA reform should require that approval of a new drug be based on comparison with existing medications to treat the same condition.

In an interview, CDER's Dr. Galson agreed that there needs to be more innovation coming from pharmaceutical companies, but said that Congress must be careful to ensure that any additional regulatory authority doesn't hamper innovation. ■

CLASSIFIEDS

Also Available at www.rheumatologynews.com

Give to the
American
Cancer Society. 

Disclaimer

RHEUMATOLOGY NEWS assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.

COLORADO

Kaiser Permanente/Colorado Permanente Medical Group, P.C., a large multispecialty group serving Kaiser Permanente members, is seeking a BE/BC Rheumatologist for an innovative pure subspecialty practice. Competitive salary and an excellent benefit package. Denver has abundant four-season outdoor activities enhanced by many community amenities. **If interested in learning more about our opportunity please feel free to contact Eileen Jones-Charlett at 303-344-7838. Or you may email me your C.V. at Eileen.T.Jones-Charlett@kp.org or fax your CV with a cover letter to 303-344-7818. EOE,M/F,V/H**

PROFESSIONAL OPPORTUNITIES

CHAIR – Department of Rheumatology

Lahey Clinic Medical Center, a 400+ physician-directed multi-specialty group practice treating more than 1 million patients annually at our state-of-the-art 295-bed hospital and outpatient clinic, is seeking a highly qualified individual to lead our premier Department of Rheumatology. As head of the department—a 6 physician group and major teaching hospital of Tufts Medical School—our ideal candidate will possess strong leadership skills and have experience with clinical research.



TREATING YOU RIGHT.™

Located in Boston's beautiful suburbs and surrounded by the great academic tradition, rich cultural diversity and historic beauty of New England, Lahey Clinic offers competitive salaries and a comprehensive benefits package. **Please send your CV and letter of interest to: John F. Beamis, Jr., M.D., Chairman, Division of Internal Medicine, Lahey Clinic, 41 Mall Road, Burlington, MA 01805; Fax: (781) 744-1975; Phone: (744) 3240; E-mail: john.f.beamis@lahey.org. EOE**

www.lahey.org

BEST READERSHIP, LOW COST QUALIFIED LEADS

2007
CLASSIFIEDS

Rheumatology News Rates

4 Column Classified Ads

From 1" to 12"

Ads starting at \$135

For Deadlines and More Information
Contact: Robin Cryan
Tel: 1-800-379-8785 or
fax your ad to 212-633-3820
Email ad to: r.cryan@elsevier.com



Rheumatology News

Elsevier-Rheumatology News
360 Park Avenue
New York, NY 10010